Annual report pursuant to Section 13 and 15(d)

Net Loss per Share Attributable to Common Stock - Schedule of Outstanding Shares of Common Stock Equivalents (Details)

v3.24.1
Net Loss per Share Attributable to Common Stock - Schedule of Outstanding Shares of Common Stock Equivalents (Details) - shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Common stock equivalents (in shares)   392,564
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Common stock equivalents (in shares) 147,707 147,707
Non-vested restricted stock awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Common stock equivalents (in shares) 1,766,417 1,375,145
Non-vested restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Common stock equivalents (in shares) 2,191,297  
Common stock warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Common stock equivalents (in shares) 240,100 240,100